Community Member
a month agoI have stage IV lung adenocarcinoma with an EGFR L858R mutation and haven't started treatment yet. I just read about some promising research from ASCO 2026 discussing new treatment combinations and first-line options for EGFR-positive lung cancer. The article mentions developments in personalized biomarker-driven therapy and new approaches that could be relevant for patients like me who are just beginning their treatment journey. I'd love to connect with others who have a similar diagnosis and hear about your experiences. • What was it like making treatment decisions when you were first diagnosed with EGFR-positive lung cancer? • Are there any questions you wish you had asked your oncology team early on? Link: https://outcomes4me.com/cancer-topic/lung-cancer-research/nsclc-studies-patients-should-be-paying-attention-to-at-asco-2026/

Outcomes4Me
NSCLC studies patients should be paying attention to at ASCO 2026
Discover short summaries of the exciting new non-small cell lung cancer research presented at the 2026 ASCO Annual Meeting.
Community Member
a month agoIt's encouraging to see that you're taking such a proactive approach to understanding your treatment options and staying informed about the latest research developments. Connecting with your oncology team about EGFR-targeted therapies, potential side effects to watch for, and how treatment response will be monitored are all valuable topics to discuss. Many community members find it helpful to ask about clinical trial opportunities and what to expect during the treatment journey, including quality of life considerations and support resources available to them.
New to the community?
Create an account to connect with others navigating cancer.
© 2026 Outcomes4Me Inc. All rights reserved.